ARYx Therapeutics(OTC) ARYX

Market CapN/A

Since IPO (2007)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

ARYx Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2025-08-11

ARYx Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2024-12-23
1 month	+0%	USD 0.00	2024-12-23
3 month	+0%	USD 0.00	2024-12-23
Year to date	+0%	USD 0.00	2024-12-23
1 year	+0%	USD 0.00	2024-06-28
3 year	-99.8%	USD 0.00	2022-06-23
5 year	-99.98%	USD 0.01	2020-08-12
Since inception	-100%	USD 8.10	2007-11-07

ARYx Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.33M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-256.19 (Low)

Dividend

$0.00

Beta (Volatility)

-256.19 (Low)

Price

$0.00

Volume

3,090

Open

$0.00

Price

$0.00

Volume

3,090

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 31, 2025

Dividend

$0.00

Beta (Volatility)

-256.19 (Low)

Price

$0.00

Volume

3,090

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 31, 2025

ARYX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ARYx Therapeutics

ARYx Therapeutics, Inc. is a biotechnology company based in Fremont, California, focused on developing innovative treatments for chronic conditions through oral medications. Established in 1997, the company employs its proprietary RetroMetabolic Drug Design technology to create unique molecular compounds that retain therapeutic effectiveness.

Products and Services

Tecarfarin (ATI-5923): An oral anticoagulant in Phase III trials for blood clot prevention
Budiodarone (ATI-2042): An oral antiarrhythmic agent in Phase IIb for atrial fibrillation
ATI-7505: An oral prokinetic agent in Phase IIb for gastrointestinal disorders

Growth Outlook

Ongoing Phase III trials for Tecarfarin may lead to significant market entry
Expansion of clinical portfolio with multiple candidates in various development stages
Potential for partnerships to enhance research and development capabilities

Financial Highlights

Recent quarterly net income of -$2.5 million, reflecting ongoing investment in R&D
Cash and cash equivalents of $2.95 million as of September 30, 2010
Trailing twelve months (TTM) cash flow from operations shows a negative trend, indicating high investment levels

ARYx Therapeutics is positioned in the healthcare sector, specifically within drug manufacturing for specialty and generic medications. The company’s focus on chronic conditions and innovative drug design may attract interest from investors looking for opportunities in the biotechnology field. The ongoing clinical trials and development of multiple drug candidates highlight the potential for future growth and market presence. However, the financial data indicates a need for careful consideration regarding the company's current cash flow and investment strategy.

AI Generated • Aug 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Fremont, CA 94555, US

ARYX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-270.76%

Return on Capital

-350.67%

Return on Assets

-267.35%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

33.46M

Volume

3.09K

Avg. Volume

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$16.73M

EBITDA

-$15.78M

Operating Cash Flow

-$20.07M

Capital Expenditure

-$52.00K

Free Cash Flow

-$20.12M

Cash & ST Invst.

$2.95M

Total Debt

$12.32M

ARYx Therapeutics Performance Analysis

ARYx Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2009-12-31	N/A
Q1	2010-03-31	N/A
Q2	2010-06-30	N/A
Q3	2010-09-30	N/A

ARYx Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2009-12-31	30.0%
Q1	2010-03-31	-4.8%
Q2	2010-06-30	50.0%
Q3	2010-09-30	31.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2010YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$2.51M

+69.2%

EBITDA

-$1.94M

+74.0%

Quarterly Fundamentals

Name

Q3 2010YOY CHG

Total Cash

$2.95M

-79.2%

Total Debt

$12.32M

-6.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.50M

-26.9%

Short Term Debt

$6.83M

+0.5%

Return on Assets

-2.67%

N/A

Return on Invested Capital

-8.39%

N/A

Free Cash Flow

-$4.05M

+40.4%

Operating Cash Flow

-$4.05M

+40.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

QEBRVirtual Medical International, Inc.

QEBRVirtual Medical International, Inc.$0.00+0.00%

NUNZNunzia Pharmaceutical Company

NUNZNunzia Pharmaceutical Company$0.00+0.00%

ONSSOnassis Holdings Corp.

ONSSOnassis Holdings Corp.$0.00+49.25%

WIBFFWest Island Brands Inc.

WIBFFWest Island Brands Inc.$0.00+0.00%

NSPDFNaturally Splendid Enterprises Ltd.

NSPDFNaturally Splendid Enterprises Ltd.$0.04+0.00%

VFRMVeritas Farms, Inc.

VFRMVeritas Farms, Inc.$0.00+0.00%

NNRXNutranomics, Inc.

NNRXNutranomics, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About ARYX

What is the current price of ARYx Therapeutics?

ARYx Therapeutics is trading at $0.00 per share.

What is the 52-week range for ARYx Therapeutics?

Over the past 52 weeks, ARYx Therapeutics has traded between $0.00 and $0.00.

How much debt does ARYx Therapeutics have?

ARYx Therapeutics total debt is unavailable.

How much cash does ARYx Therapeutics have on hand?

ARYx Therapeutics does not have cash on hand data available.

What is ARYx Therapeutics’s dividend yield?

ARYx Therapeutics does not currently have a dividend yield.

ARYx Therapeutics(OTC) ARYX

ARYx Therapeutics Financials at a Glance

ARYX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ARYx Therapeutics

ARYX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ARYx Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARYX

What is the current price of ARYx Therapeutics?

What is the 52-week range for ARYx Therapeutics?

How much debt does ARYx Therapeutics have?

How much cash does ARYx Therapeutics have on hand?

What is ARYx Therapeutics’s dividend yield?

Premium Investing Services